• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Human psychopharmacology: clinical and experimental >Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
【24h】

Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.

机译：氯丙咪嗪、氟西汀和CYP2D6代谢抑郁症患者的能力。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cytochrome P450-2D6 may be involved in the metabolism of many drugs such as psychotropic drugs and its genetic polymorphism is responsible for inter-individual differences in the therapeutic effect and toxicity of these drugs. Moreover with the same genetic basis, CYP2D6 metabolic capacity variations are observed. Different factors of variation may be involved, among them the prescribed drugs.The aim of this study was to compare the influence of two types of antidepressants, tricyclic (clomipramine) and serotonergic specific recapture inhibitor (SSRI) (fluoxetine), on the CYP2D6 metabolic capacity of depressed inpatients. The CYP2D6 phenotype (dextromethorphan test) was determined in 56 genotyped (PCR-SSCP) depressed caucasian inpatients with a heterozygous genotype. Forty-five subjects were treated with clomipramine and eleven received fluoxetine. The dextromethorphan metabolic ratio (MR) median was significantly higher in the fluoxetine group (0.255) than in the clomipramine group (0.083, p < 0.014).In this study, fluoxetine involved a greater decrease of CYP2D6 metabolic capacity than clomipramine. Clinical implications and the possible connection between a decreased CYP2D6 activity and adverse drug effects were discussed. Caution should be taken when drugs with a low therapeutic index must be coprescribed in such patients.
机译：细胞色素P450-2D6可能参与许多药物代谢等精神药物及其基因多态性是负责任的inter-individual差异这些药物的疗效和毒性。而且相同的遗传基础,CYP2D6代谢能力的变化。不同因素的变异可能涉及,其中规定的药物。研究比较两种类型的影响抗抑郁药、三环(氯丙咪嗪)和血清素激活的特定夺回抑制剂)(氟西汀),CYP2D6的代谢能力抑郁症住院患者。在56(右美沙芬测试)决定基因分型(PCR-SSCP)抑郁的白种人住院病人杂合的基因型。45受试者接受氯丙咪嗪和11个收到氟西汀。右美沙芬代谢率(MR)值显著的高于氟西汀组比氯丙咪嗪组(0.255)(0.083,p< 0.014)。更大的降低CYP2D6的代谢能力氯丙咪嗪。可能CYP2D6减少之间的联系活动和药物不良影响进行了讨论。应采取谨慎当药物较低必须coprescribed这样治疗指数病人。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号